A trial of fruquintinib, trastuzumab, and chemo for HER2-positive stomach cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of three drugs (fruquintinib, trastuzumab, and XELOX chemotherapy) as the first treatment for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The goal is to see if this combination is safe and effective for shrinking tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced stomach or gastroesophageal junction cancer that tests positive for HER2.
- You have not received any prior treatment for cancer that has spread.
- You are in generally good health (able to perform daily activities without help).
- Your major organs (kidneys, liver, blood cells) are working well enough, based on blood tests.
- You are willing to use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an oral targeted therapy (fruquintinib), an immunotherapy (PD-1 inhibitor), and chemotherapy (FOLFOX) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this triplet therapy helps control the cancer better than standard treatments.
This trial tests a combination of two medications—fruquintinib (a targeted therapy) and a PD-1 inhibitor (immunotherapy)—as a first maintenance treatment after initial chemotherapy for advanced gastric cancer. The goal is to see if this combination can help control the cancer longer.
This trial tests a combination of three drugs after surgery for HER2-positive stomach cancer: an immunotherapy (serplulimab), a targeted therapy (trastuzumab), and chemotherapy (SOX). The goal is to see if this treatment helps prevent the cancer from coming back.
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
This trial tests adding fruquintinib (a targeted drug that blocks blood vessel growth) to chemotherapy after surgery for HER2-negative stomach or gastroesophageal junction cancer. It is for patients whose tumor did not respond well to previous treatment before surgery.
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.